Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Immunization Schedules in Melanoma
NCT00020358Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2000
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gp100:209-217, tyrosinase peptide in melanoma, sponsored by National Cancer Institute. Started Sep 2000; status: completed.
02
Drugs
gp100:209-217tyrosinase peptide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00020358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020358.